company background image
ACR logo

Acrux ASX:ACR Stock Report

Last Price

AU$0.053

Market Cap

AU$15.4m

7D

0%

1Y

27.7%

Updated

31 Oct, 2024

Data

Company Financials +

ACR Stock Overview

Engages in the development and commercialization of generic and topically applied pharmaceutical products in Australia, Europe, the United States, and internationally.

ACR fundamental analysis
Snowflake Score
Valuation3/6
Future Growth6/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Acrux Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Acrux
Historical stock prices
Current Share PriceAU$0.053
52 Week HighAU$0.099
52 Week LowAU$0.035
Beta1.21
11 Month Change0%
3 Month Change-20.90%
1 Year Change27.71%
33 Year Change-55.83%
5 Year Change-77.92%
Change since IPO-94.11%

Recent News & Updates

Recent updates

Here's Why Shareholders May Want To Be Cautious With Increasing Acrux Limited's (ASX:ACR) CEO Pay Packet

Nov 16
Here's Why Shareholders May Want To Be Cautious With Increasing Acrux Limited's (ASX:ACR) CEO Pay Packet

It's Unlikely That Acrux Limited's (ASX:ACR) CEO Will See A Huge Pay Rise This Year

Nov 16
It's Unlikely That Acrux Limited's (ASX:ACR) CEO Will See A Huge Pay Rise This Year

We Think Acrux (ASX:ACR) Needs To Drive Business Growth Carefully

Sep 21
We Think Acrux (ASX:ACR) Needs To Drive Business Growth Carefully

Here's Why We're Watching Acrux's (ASX:ACR) Cash Burn Situation

May 20
Here's Why We're Watching Acrux's (ASX:ACR) Cash Burn Situation

Is Acrux (ASX:ACR) In A Good Position To Invest In Growth?

Feb 04
Is Acrux (ASX:ACR) In A Good Position To Invest In Growth?

Here's What We Think About Acrux's (ASX:ACR) CEO Pay

Dec 14
Here's What We Think About Acrux's (ASX:ACR) CEO Pay

Shareholder Returns

ACRAU PharmaceuticalsAU Market
7D0%0.2%-0.5%
1Y27.7%74.7%19.4%

Return vs Industry: ACR underperformed the Australian Pharmaceuticals industry which returned 74.7% over the past year.

Return vs Market: ACR exceeded the Australian Market which returned 19.4% over the past year.

Price Volatility

Is ACR's price volatile compared to industry and market?
ACR volatility
ACR Average Weekly Movement9.0%
Pharmaceuticals Industry Average Movement12.0%
Market Average Movement8.7%
10% most volatile stocks in AU Market17.8%
10% least volatile stocks in AU Market3.6%

Stable Share Price: ACR has not had significant price volatility in the past 3 months compared to the Australian market.

Volatility Over Time: ACR's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1998n/aMichael Kotsaniswww.acrux.com.au

Acrux Limited, together with its subsidiaries, engages in the development and commercialization of generic and topically applied pharmaceutical products in Australia, Europe, the United States, and internationally. The company provides estradiol transdermal sprays for women under the Evamist and Lenzetto brand names for the treatment of flushes associated with menopause; Dapsone 5% and Dapsone 7.5% which are gels for the treatment of acne vulgaris; and Prilocaine 2.5% and Lidocaine 2.5%, a topical anaesthetic cream. It is also involved in the development of Efinaconazole, a topical solution used to treat fungal infections of toenails; Nitroglycerin 0.4%, an ointment for the treatment of pain caused by chronic anal fissure; and Acyclovir 5%, a cream for the treatment of cold sores.

Acrux Limited Fundamentals Summary

How do Acrux's earnings and revenue compare to its market cap?
ACR fundamental statistics
Market capAU$15.41m
Earnings (TTM)-AU$5.80m
Revenue (TTM)AU$5.09m

3.0x

P/S Ratio

-2.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ACR income statement (TTM)
RevenueAU$5.09m
Cost of RevenueAU$6.38m
Gross Profit-AU$1.28m
Other ExpensesAU$4.52m
Earnings-AU$5.80m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.02
Gross Margin-25.22%
Net Profit Margin-113.93%
Debt/Equity Ratio45.4%

How did ACR perform over the long term?

See historical performance and comparison